Lotus Pharmaceutical Co., Ltd. reported third-quarter earnings with revenues of NT$5.2 billion and earnings per share of NT$5.98, leading to a 2.6% drop in share price. Analysts maintain a price target of NT$399, forecasting a 22% revenue increase to NT$21.4 billion in 2025, though growth is expected to lag behind industry averages. Despite reaffirmed estimates, concerns remain, including one warning sign for investors.